Product Information
PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $3.2323 per EA under NDC 00480329756. Its NADAC has been published 49 times since Sep 17, 2025.
FDA first approved this application on Jun 25, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
3.75; 23 mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480329756
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
PHENTERMINE HYDROCHLORIDE; TOPIRAMATEApproval Type
Generic (ANDA)
FDA Application
ANDA204982FDA Approved
6/25/2024
TE Code
AB
On Market Since
5/7/2025
Pharmacological Classes
Price Statistics
The NADAC for PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE has been published 49 times since Sep 17, 2025, and over the history we have for it it has risen 23.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.2323 per EA |
|---|---|
| All-time high | $3.5336 (Jan 14, 2026) |
| All-time low | $2.6225 (Sep 17, 2025) |
| 52-week high | $3.5336 |
| 52-week low | $2.6225 |
| Median price | $3.1861 |
| Average price | $3.1141 |
| Largest weekly change | +11.1% (Oct 22, 2025) |
| Weeks tracked | 49 |
| Tracking since | Sep 17, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Phentermine and topiramate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $3.2323 per EA (NDC 00480329756), effective Aug 19, 2026.
How has the price of PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE has risen 23.2%. It has been tracked across 49 weekly CMS publications since Sep 17, 2025.
What are the highest and lowest recorded NADAC prices for PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE?
Since Sep 17, 2025, the NADAC for PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE has ranged from a low of $2.6225 (Sep 17, 2025) to a high of $3.5336 (Jan 14, 2026), with a median of $3.1861 per EA.
Are there cheaper alternatives to PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE?
PHENTERMINE-TOPIRAMATE ER 3.75-23 MG CAPSULE (NDC 00480329756) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.